Ranbaxy gets tentative US FDA nod for Amlodipine Tab

New Delhi, June 20 (UNI) Ranbaxy Laboratories Limited (RLL), today announced that it has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market Amlodipine Besylate Tablets in its 2.5 mg (base), 5 mg (base) and 10 mg (base) variants ''We are pleased to receive this tentative approval for Amlodipine Besylate Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA,'' said Ranbaxy Pharmaceuticals Inc, USA Vice President (Sales and Marketing) Jim Meehan, in a statement.

This product will further expand our product portfolio of affordable generic alternatives, he added.

The total annual market sales for Amlodipine Besylate Tablets were 2.79 billion dollars in March 2007.

Ranbaxy Pharmaceuticals Inc (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL).

RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

UNI